09/14/2016 10:25:44 AM FROM: LABCORP LCLS F6 TO:LISA P Woodson Merre' TO: LabCorp Raritan LabCorp or ee Raritan, NJ 08869-1800 Specimea Number Pwtieat ID Coowol Number Account Number Account Phooe Number Route asaase-azav-o | | noateaoasua | Siiasoo | gemma | "Ss | jeot Last Name Account Address Patient Patieot Middle Name Patient Phooe Total Volume 212-750-9895 Date of Birth 01/20/53 |e | 9 E 71ST ST NEW YORK NY SE 09/08/16 08:23 09/08/16 Woodson Merrell 44 E 67th st New York NY 10065 Page 1 of 9 r Phone: 800-631-5250 UPIN: A62553 NMR LipoProfile; Heavy Metals Profile II, Blood; CBC With Differential/Platelet; Comp. Metabolic Panel (14); IFE and PE, Serum; Urinalysis, Routine; Lipid Panel; Iron and TIBC; Testosterone,Freet+Weakly Bound; Ca+PTH Intact; Vitamin B12 and Folate; Lyme Ab/Western Blot Reflex; Hemoglobin Alc; Thyroxine (T4) Free, Direct, S; DHEA-Sulfate; Cortisol; TSH; Rheumatoid Arthritis Factor; Prostate-Specific Ag, Serum; IGF-1; Vitamin D, 25-Hydroxy; Panel 083935; C-Reactive Protein, Cardiac; HCV Ab w/Rflx to Verification; ANA w/Reflex; Homocyst(e)ine, Plasma; Uric Acid, Serum; LDH; GGT; Magnesium, Serum; Zinc, Plasma or Serum; Insulin; Ferritin, Serum; Test Code Change; Venipuncture TESTS FLAG UNITS REFERENCE INTERVAL LAB NMR LipoProfile LDL Particle Number o1 LDL-P 1562 High nmol/L <1000 o1 Low < 1000 Moderate 1000 - 1299 Borderline-High 1300 - 1599 High 1600 - 2000 Very High > 2000 Lipids 01 LDL-C mg/dL o- 99 Triglyceride result indicated is too high for an accurate LDL cholesterol estimation. Optimal < 100 Above optimal 100 - 129 Borderline 130 - 159 High 160 - 189 Very high > 189 Comment : ol LDL-C is inaccurate if patient is non-fasting. HDL-C 27 Low mg/dL >39 o1 Triglycerides 476 High mg/dL 0 - 149 o1 Cholesterol, Total 214 High mg/d 100 - 199 o1 LDL and HDL Particles o1 HDL-P (Total) 22.5 Low umol/L >=30.5 01 Small LDL-P 1243 High nmol/L <=527 01 LDL Size 19.7 nm >20.5 01 |Epstein, Jeffrey oT C‘d’:«C2S 2-436 —-4247—O [Seg BSI] 09/14/16 10:25 ET DUPLICATE FINAL REPORT Page 1 of 8 ‘This document contains private and confidential health infonnation protected by state and federal law. If you have received this document in error, please call 800-631-5250 ©2004-16 Laboratary Corporation of America ® Holdings All Rights Reserved DOCI Ver: 1.49 EFTA00287152

--=PAGE_BREAK=--

09/14/2016 10:25:44 AM FROM: LABCORP LCLS F6 TO: LABCORP Page2 of 9 TO: LISA P Woodson Me: LabCorp Raritan LabCorp 69 First Avenue Raritan, NJ 08869-1800 Phone: 800-631-5250 Patient Name Specimen Number 252"436- 4247-0 S| = Ls 09713718 |_m | 3707/19 | 1730/5: 31143092 anaiassesis 09/08/16 08:23 | osriarsa | | aarersan | cosares | (ests eesunr FEAG UMTS REFERENCE INTERVAL EAB] ** INTERPRETATIVE INFORMATION** PARTICLE CONCENTRATION AND SIZE <--Lower CVD Risk Higher CVD Risk--> LDL AND EDL PARTICLES Percentile in Reference Population HDL-P (total) High 75th 50th 25th Low >34.9 34.9 30.5 26.7 <26.7 Small LDL-P Low 25th 50th 75th High <117 117 527 839 >839 LDL Size <-Large (Pattern A)-> <-Small (Pattern B)-> 23.0 20.6 20.5 19.0 Comment : 01 Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account. These assays were developed and their performance characteristics determined by LipoScience. These assays have not been cleared by the US Food and Drug Administration. The clinical utility of these laboratory values have not been fully established. Insulin Resistance Score 01 LP-IR Score 91 High <=45 ol INSULIN RESISTANCE MARKER <--Insulin Sensitive Insulin Resistant--> Percentile in Reference Population Insulin Resistance Score LP-IR Score Low 25th 50th 75th High <27 27 45 63 >63 Comment : ol LP-IR Score is inaccurate if patient is non-fasting. The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. The LP-IR score listed above has not been cleared by the US Food and Drug Administration. Heavy Metals Profile II, Blood Lead, Blood None Detected ug/dL o- 19 o1 Environmental Exposure: WHO Recommendation <20 Occupational Exposure: OSHA Lead Std 40 BEL 30 Detection Limit = 1 Epstein, Jeffrey Po C(tstCSC*d':«C2'5' 2436-42470 09/14/16 10:25 ET DUPLICATE FINAL REPORT Page 2 of 8 ‘This document contains private and confidential health information protected by state and federal law. ©2004—16 Laboratory Corporation of America @ Holdings If you have received this document in error, please call 800-631-5250 All Rights Reserved DOCI Ver: 1.49 EFTA00287153

--=PAGE_BREAK=--

09/14/2016 10:25:44 AM FROM: LABCORP LCLS F6 LABCORP 3 of 9 TO:LISA P Woodson _— Page ‘ LabCorp Raritan LabCorp ore aa eatin NJ 08869-1800 Phone: 800-631-5250 Specimen Number pstein, Jeffre 252-436-4247-0 1 Number Date aod Time Date Reported AgetYMiD) | Date of Bich [siueese |__| setecanie | erent oneal ooatite | overs [eran TESTS REFERENCE INTERVAL LAB Arsenic, Blood 4 ug ey) 2 - 23 01 Detection Limit = 1 Mercury, Blood 2.2 ug/L 0.0 = 14.9 o1 Environmental Exposure: <15.0 Occupational Exposure: BEI - Inorganic Mercury: 15.0 Detection Limit = 1.0 Cadmium, Blood None Detected ug/L 0.0 - 1.2 01 Environmental Exposure: Nonsmokers 0.3 - 1.2 Smokers 0.6 - 3.9 Occupational Exposure: OSHA Cadmium std 5.0 BEI 5.0 Detection Limit = 0.5 cBC With Differential/Platelet WBC 5.8 x10E3/uL 3.4 - 10.8 02 RBC 4.95 x10E6/uL 4.14 - 5.80 02 Hemoglobin 14.1 g/dL 12.6 - 17.7 02 Hematocrit 41.9 % 37.5 - 51.0 02 MCV 85 £L 79 - 97 02 MCH 28.5 pg 26.6 - 33.0 02 MCHC 33.7 g/dL 31.5 - 35.7 02 RDW 14.4 % 12.3 - 15.4 02 Platelets 232 x10E3/uL 150 - 379 02 Neutrophils 51 % 02 Lymphs 32 % 02 Monocytes 9 % 02 Eos 7 % 02 Basos 1 % 02 Neutrophils (Absolute) 3.0 x10E3/uL 1.4 - 7.0 02 Lymphs (Absolute) 1.8 x10E3/uL 0.7 - 3.1 02 Monocytes (Absolute) 0.5 x10E3/uL 0.1 - 0.9 02 Eos (Absolute) 0.4 x10E3/uL 0.0 - 0.4 02 Baso (Absolute) 0.0 x10E3/uL 0.0 = 0.2 02 Immature Granulocytes te) % 02 Immature Grans (Abs) 0.0 x10E3/uL 0.0 - 0.1 02 Comp. Metabolic Panel (14) Glucose, Serum 96 mg/dL 65 - 99 02 BUN 16 mg/dL 8 - 27 02 Creatinine, Serum 0.94 mg/dL 0.76 - 1.27 02 eGFR If NonAfricn Am 86 mL/min/1.73 >59 eGFR If Africn Am 99 mL/min/1.73 >59 [Epstein, Jeffrey] CC‘“‘“‘CSC*dS:CO25 2-436 42.47—O | Seq 8516 | 09/14/16 10:25 ET DUPLICATE FINAL REPORT Page 3 of 8 ‘This document contains private and confidential health information protected by state and federal law. ©2004-—16 Laboratory Corporation of America © Holdings If you have received this document in exror, please call 800-631-5250 Al Rights Reserved EFTA00287154

--=PAGE_BREAK=--

09/14/2016 10:25:44 AM FROM: LABCORP \cVoodso LABCORP 4o0 9 TO: LISA P Sdson Mor Page ‘ LabCorp Raritan LabCorp 69 First Avenue Raritan, NJ 08869-1800 ae B00-631- 5250 Patieat Name 252-436 (347-0 (ie |=" pena Ln wr 1730/83 31143092 10416404914 | 09/08/16 08:23] 09/13/16 63/07/19 SoN/Creatinine Ratio Sodium, Serum 139 mmol/L Potassium, Serum 4.4 mmol/L Chloride, Serum 99 mmol/L Carbon Dioxide, Total 22 mmol/L Calcium, Serum 9.5 mg/dL 8.6 - 10.2 02 Protein, Total, Serum 6.7 g/dL 6.0 - 8.5 02 Albumin, Serum 4.3 g/dL 3.6 - 4.8 02 Globulin, Total 2.4 g/dL 1.5 - 4.5 A/G Ratio 1.8 1.1 - 2.5 Bilirubin, Total 0.8 mg/dL 0.0 - 1.2 02 Alkaline Phosphatase, Ss 63 Iu/L 39 - 117 02 AST (SGOT) 30 Iu/L o- 40 02 ALT (SGPT) 42 Iu/L Oo- 44 02 IFE and PE, Serum Immunoglobulin G, Qn, Serum 1056 mg/dL 700 - 1600 02 Immunoglobulin A, Qn, Serum 224 mg/dL 61 - 437 02 Immunoglobulin M, Qn, Serum 42 mg/dL 20 - 172 02 Albumin 3.6 g/dL 2.9 - 4.4 02 Alpha-1-Globulin 0.2 g/dL 0.0 - 0.4 02 Alpha-2-Globulin 0.8 g/dL 0.4 - 1.0 02 Beta Globulin 1.0 g/dL 0.7 - 1.3 02 Gamma Globulin 1.0 g/dL 0.4 - 1.8 02 M-Spike Not Observed g/dL Not Observed 02 Globulin, Total 3.1 g/dL 2.2 - 3.9 A/G Ratio 1.2 0.7 - 1.7 Immunofixation Result, Serum 02 An apparent normal immunofixation pattern. Please note: 02 Protein electrophoresis scan will follow via computer, mail, or courier delivery. Urinalysis, Routine Urinalysis Gross Exam 02 Specific Gravity 1.028 1.005 - 1.030 02 PH 5.5 5.0 - 7.5 02 Urine-Ccolor Yellow Yellow 02 Appearance Clear Clear 02 WBC Esterase Negative Negative 02 Protein Negative Negative/Trace 02 Glucose Negative Negative 02 Ketones Negative Negative 02 Occult Blood Trace Abnormal Negative 02 Bilirubin Negative Negative 02 Urobilinogen, Semi-Qn 0.2 EU/dL 0.2 - 1.0 02 Nitrite, Urine Negative Negative 02 | Epstein, Jeffrey | CC 252 436-4247-0 | Seq ¥ 8516 | 09/14/16 10:25 ET DUPLICATE FINAL REPORT Page 4 of 8 ‘This document contains private and confidential health information protected by state and federal law. ©2004-16 Laboratory Corporation of America ® Holdings If you have received this document in error, please call 800-631-5250 ‘All Rights Resesves EFTA00287155

--=PAGE_BREAK=--

09/14/2016 10:25:44 AM FROM: LABCORP LCLS Fé LABCORP Page5 of 9 + O:LISA P Woodson Merrel LabCorp Raritan LabCorp ona Raritan, NJ 08869-1800 Phone: 800-631-5250 Patient Name Specimen Number Patiect ID Cootro] Number Date aad Time Collected [ Dare Repor ‘s Age(y/M/D) Date of Bicth REFERENCE INTERVAL LAB Wicroscopic 3 exanination See S below 02 WBC 0-5 /hpf o- 5 02 RBC 0-2 /hpf o- 2 02 Epithelial Cells (non renal) None seen /hpf 0-10 02 Mucus Threads Present Not Estab. 02 Bacteria None seen None seen/Few 02 Lipid Panel Cholesterol, Total 214 High mg/dL 100 - 199 02 Triglycerides 470 High mg/dL 0 - 149 02 HDL Cholesterol 27 Low mg/dL >39 02 Comment 02 According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD. VLDL Cholesterol Cal mg/dL 5 - 40 The calculation for the VLDL cholesterol is not valid when triglyceride level is >400 mg/dL. LDL Cholesterol Calc mg/dL o- 99 Triglyceride result indicated is too high for an accurate LDL cholesterol estimation. Iron and TIBC Iron Bind.Cap.(TIBC) 302 ug/dL 250 - 450 UIBC 219 ug/dL 111 - 343 02 Iron, Serum 83 ug/dL 38 - 169 02 Iron Saturation 27 & 15 - 55 Testosterone,Free+Weakly Bound Testosterone, Serum 153 Low ng/dL 348 - 1197 02 Comment : Adult male reference interval is based on a population of lean males up to 40 years old. Testost., % Free+Weakly Bound 31.6 & 9.0 - 46.0 ol Testost., F+W Bound 48.3 ng/dL 40.0 - 250.0 Ca+PTH Intact PTH, Intact 65 pg/mL 15 - 65 02 Intact PTH 02 Interpretation Intact PTH Calcium (pg/mL) (mg/dL) Normal 15 - 65 8.6 - 10.2 Primary Hyperparathyroidism >65 >10.2 Secondary Hyperparathyroidism >65 <10.2 Non-Parathyroid Hypercalcemia <65 >10.2 Hypoparathyroidism <15 < 8.6 (Epstein, Jeffrey —~«4| | 252-436-4247-0 | scqissié] 09/14/16 10:25 ET DUPLICATE FINAL REPORT Page 5 of 8 This document contains private and confidential health infonnation protected by state and federal law. ©2004~-16 Laboratory Corporation of America ® Holdings If you have received this document in error, please call 800-631-5250 All Rights Reserved EFTA00287156

--=PAGE_BREAK=--

09/14/2016 10:25:44 AM FROM: LABCORP LCLS F6 TO: LABCORP Page6 of 9 + TO:LISA P Woodson Merre'! LabCorp Raritan LabCorp 69 First Avenue Raritan, NJ 08869-1800 Phone: 800-631-5250 Patieat Name ‘Specimen Number ["siaseos |__| aosteaoasia | osvossie 00:23] on/13/i6 1/208 TESTS RESULT REFERENCE INTERVAL LAB Non-Parathyroid Sypocalcenia .or - 65 < 8.6 Vitamin B12 and Folate Vitamin B12 945 pg/mL 211 - 946 02 Folate (Folic Acid), Serum 9.9 ng/mL >3.0 02 Note: 02 A serum folate concentration of less than 3.1 ng/mt is considered to represent clinical deficiency. Lyme Ab/Western Blot Reflex Lyme IgG/IgM Ab <0.91 IsR 0.00 - 0.90 02 Negative <0.91 Equivocal 0.91 - 1.09 Positive >1.09 Lyme Disease Ab, Quant, IgM <0.80 index 0.00 - 0.79 02 Negative <0.80 Equivocal 0.80 - 1.19 Positive >1.19 IgM levels may peak at 3-6 weeks post infection, then gradually decline. Hemoglobin Alc Hemoglobin Alc 5.8 High % 4.8 - 5.6 02 Please Note: 02 Pre-diabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0 Thyroxine (T4) Free, Direct, Ss T4,Free(Direct) 1.13 ng/dL 0.82 - 1.77 02 DHEA-Sul fate 155.3 ug/dL 48.9 - 344.2 02 Cortisol 14.1 ug/dL 02 Cortisol AM 6.2 - 19.4 Cortisol PM 2.3 - 11.9 TSH 1.800 ulU/mL 0.450 - 4.500 02 Rheumatoid Arthritis Factor RA Latex Turbid. 5.8 IU/mL 0.0 - 13.9 02 Epstein, Jeffrey pos 252-436 4247-0 09/14/16 10:25 ET DUPLICATE FINAL REPORT Page 6 of 8 This document contains private and confidential health information protected by state and federal law. ©2004—16 Laboratory Corporation of America © Holdings If you have received this document in error, please call 800-631-5250 sar. orereeiprs fer: 1.49 EFTA00287157

--=PAGE_BREAK=--

09/14/2016 10:25:44 AM FROM: LABCORP LCLS F6 To: LABCORP Page 7 of 9 ir TO:LISA P Woodson Me LabCorp Raritan LabCorp 69 First Avenve Raritan, NJ 08869-1800 Phone: 800-631-5250 Paticot Name Specimen Number Epstein, Jeffr 252-436-4247-0_ | STuiseos._| Date and Time Collected | Date Reported Age(¥M/D) Date of Bich 31143092 spaseananas 09/08/16 08:23] 09/13/16 63/07/19 | 01/20/53 a eee Ere ee Prostate-Specific Ag, Serum Prostate Specific Ag, Serum 0.6 ng/mL 0.0 - 4.0 02 Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. IGF-1 Insulin-Like Growth Factor I 151 ng/mL 49 - 188 01 Vitamin D, 25-Hydroxy 34.0 ng/mL 30.0 - 100.0 02 Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30. Panel 083935 HIV Screen 4th Generation wRfx Non Reactive Non Reactive 02 C-Reactive Protein, Cardiac 3.39 High mg/L 0.00 - 3.00 02 Relative Risk for Future Cardiovascular Event Low <1.00 Average 1.00 - 3.00 High >3.00 HCV Ab w/Rflx to Verification HCV Ab <0.1 s/co ratio 0.0 - 0.9 02 Comment : 02 Non reactive HCV antibody screen is consistent with no HCV infection, unless recent infection is suspected or other evidence exists to indicate HCV infection. Epstein, Jeffre’ Po 252-436 -42.47-0 09/14/16 10:25 ET DUPLICATE FINAL REPORT Page 7 of 8 This document contains private and confidential health information protected by state and federal law. ©2004-16 Laboratory Corporation of America ® Holdings If you have received this document in error, please call 800-631-5250 All Rights Reserved DOCI Ver: 1.49 EFTA00287158

--=PAGE_BREAK=--

09/14/2016 10:25:44 AM FROM: LABCORP LCLS F6 ie | LABCORP Page 8 of 9 or TO:LISA P Woodson M LabCorp Raritan LabCorp or a Raritan, NJ 08869-1800 Phone: 800-631-5250 Paticot Name Specimen Number Epstein, Jeffrey 252-436-4247-0 [Straoos |" ___[rossesoasia | os7oerte obsza| onvis/is | m | esvorvis | o1/20vs3| 31143092 10416404914 | 09/08/16 08:23] 09/13/16 63/07/19 | 01/20/53 ANA w/Reflex ANA Direct Negative Negative 02 Homocyst(e)ine, Plasma 16.0 High umol/L 0.0 - 15.0 02 Uric Acid, Serum Uric Acid, Serum 7.1 mg/dL 3.7 - 8.6 02 Please Note: 02 Therapeutic target for gout patients: <6.0 LDH 171 Iu/L 121 - 224 02 GGT 24 IU/L 0 - 65 02 Magnesium, Serum 2.0 mg/dL 1.6 - 2.3 02 Zinc, Plasma or Serum 89 ug/dL 56 - 134 ol Detection Limit = 5 Insulin 11.1 ulU/mL 2.6 - 24.9 02 Ferritin, Serum 98 ng/mL 30 = 400 02 Test Code Change 02 **Effective May 8, 2016, HIV-1/0/2 Antibodies, Preliminary Test with** Confirmation (Third Generation) has been discontinued. Please note the HIV-1/0/2 Antibodies, Preliminary Test with Confirmation was updated to HIV-1/0/2 Antigen/Antibody (Fourth Generation) Preliminary Test with Cascade reflex to Supplementary Testing by LabCorp. For future orders, please use the HIV-1/0/2 Antigen/Antibody test number 083935. Contact your LabCorp Key Account Executive to request new custom profile(s) containing 083935. ol BN LabCorp Burlington Dir: William F Hancock, MD 1447 York Court, Burlington, NC 27215-3361 02 RN LabCorp Raritan Dir: Araceli B Reyes, MD 69 Pirst Avenue, Raritan, NJ 08869-1800 For inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-631-5250 Epstein, Jeffrey Pod 252-436 4247-0 09/14/16 10:25 ET DUPLICATE FINAL REPORT Page 8 of 8 This docunent contains private and confidential health information protected by state and federal law, ©2004-16 Laboratory Corporation of America ® Holdings If you have received this document in error, please call 800-631-5250 All Rigs Reeve DOCI Ver: 1.4 EFTA00287159

--=PAGE_BREAK=--

pecial Raritan New Jersey Serum Immunofixation and Electrophoresis OE A Serum Proteins IFE Gel T44385 Sample 45 09/09/2016 13:51:29: 252436424709 Accession Number 252436424708 Physician ID MERRELL W Patient Name Epstein, Jeffrey Account Address 1 Total Protein 67 Account Address 2 44 E 67th St Patient ID Account Address 3 New York, NY 10065 Birthdate 1/20/1953 Account No/Name 31143092-Woodson Merrell [Sima] Comments An apparent normal immunofixation pattern. EFTA00287160